| Mifepristone | Corcept Terapeutics | ||
| 300 mg; Tablet, Oral |
Less Than $1000 mn
|
||
|
Less Than 5
|
Less Than 5
|
||
|
Less Than 5
|
None | ||
|
Less Than 5
|
None | ||
| Indicated to control hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. | |||
|
Yes
| |||
| Korlym | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 | Patent 6 | Patent 7 | Patent 8 | Patent 9 | Patent 10 | Patent 11 | Patent 12 | Patent 13 | Patent 14 | Patent 15 | Patent 16 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| **** | *** ********* (***** ******) | *** ********* (***** ******) | **** ** *** *, **** (***** ******) | **** ** *** *, **** (***** ******) | *** ** ** / ******** ** ** (***** ******) | *** ********* (***** ******) | *** ********* (***** ******) | ******** *** ** *** | ******** *** ** *** | **** ** ***** **, **** (***** ******) | *** ********* (***** ******) | ******** *** ** *** | *** ** ** / ******** ** ** | ******** *** ** *** | *** ********* (***** ******) | *** ********* (***** ******) |
| *** ****** | *** ********* | *** ********* | *** ********* | *** ********* | ******* | *** ********* | *** ********* | ******* | ******* | *** ********* | *** ********* | ******* | ******* | ******* | *** ********* | *** ********* |
| ***** | *** ********* | *** ********* | *** ********* | *** ********* | ******* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | ******* | ******* | ******* | *** ********* | *** ********* |
| Company | FTF Status / 180 days exclusivity | 30-Months stay | Current Litigation Status | Current Approval Status | Likelihood of launch |
|---|---|---|---|---|---|
| **** | *** \ *** | **** **, **** | ********* *** ** ** / ******** ** ** | ******** | ******** ** *** **, **** |
| *** ****** | ** \ ** | *** **, **** | ******* | **** | ** *** **, **** |
| ***** | ** \ ** | *** **, **** | ******* | **** | ** *** **, **** |
Download ParaIV Report